Thrombostatin-A Thrombin Receptor Inhibitor

Information

  • Research Project
  • 7072202
  • ApplicationId
    7072202
  • Core Project Number
    R44HL055907
  • Full Project Number
    5R44HL055907-05
  • Serial Number
    55907
  • FOA Number
    PA-04-28
  • Sub Project Id
  • Project Start Date
    4/1/1996 - 28 years ago
  • Project End Date
    11/30/2007 - 17 years ago
  • Program Officer Name
    GANGULY, PANKAJ
  • Budget Start Date
    6/1/2006 - 18 years ago
  • Budget End Date
    11/30/2007 - 17 years ago
  • Fiscal Year
    2006
  • Support Year
    5
  • Suffix
  • Award Notice Date
    6/29/2006 - 18 years ago
Organizations

Thrombostatin-A Thrombin Receptor Inhibitor

[unreadable] DESCRIPTION (provided by applicant): [unreadable] The purpose of this proposal is for Thromgen, Inc. to transition its preclinical agent, Thrombostatin(tm), into human clinical trials. Thromgen, Inc. has created an agent that is a low affinity direct thrombin inhibitor and a higher affinity binder to the thrombin activation site on both human protease receptor 1 (PAR1) and 4 (PAR4) to prevent thrombin cleavage of these substrates. Both small and large animal studies demonstrate that this agent delays the time to thrombosis in both coronary and carotid artery thrombosis models in both the mouse and dog. Thromgen, Inc. now seeks funding to support toxicology studies for its best agent, Thrombostatin(tm), for the preparation of an Investigator New Drug (IND) application to the FDA. The specific aims are two-fold: [unreadable] Specific Aim #1: Toxicology investigations will be performed in rodent and nonrodent animal species for the preparation of a Thrombostatin(tm) IND application to the FDA for a single intravenous administration. Specific Aim #2: Analytical studies and genotoxicity investigations on the agent will be performed for FDA requirements for an IND application. The purpose of this program is multifaceted. First, the safety of the current Thrombostatin(tm) for human use will be determined. Second, the preparation of an IND application for its human use for one indication will be achieved. Thrombostatin(tm) has the opportunity to be a first-in-its-class thrombin receptor activation antagonist. [unreadable] [unreadable]

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R44
  • Administering IC
    HL
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    606945
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    839
  • Ed Inst. Type
  • Funding ICs
    NHLBI:606945\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    THROMGEN, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    ANN ARBOR
  • Organization State
    MI
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    48107
  • Organization District
    UNITED STATES